8-K current report · filed Oct 30, 2026

Aurinia Pharmaceuticals Inc. (AUPH) 8-K Current Report: October 30, 2026

Item EX-99.1Item 2.02AUPH overview

Short answer

Aurinia Pharmaceuticals Inc. (AUPH) filed an 8-K current report with the SEC on October 30, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item 2.02 (Results of Operations and Financial Condition). Aurinia announced financial results for the three months ended September 30, 2026.

Aurinia Pharmaceuticals Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Aurinia announced financial results for the three months ended September 30, 2026
  • Exhibit 99.1 contains the detailed quarterly financial results for investor review

Item EX-99.1 · Exhibit EX-99.1

  • Q3 revenue $83.7M, up 14%; nine-month revenue $244.6M, up 19%, led by LUPKYNIS sales
  • Nine-month net income $103.5M, up 35%, with operating cash flow $131.5M, up 46%
  • 2026 revenue guidance raised to $325M-$330M; product-sales guidance narrowed to $310M-$315M
  • Cash, restricted cash and investments reached $486.9M; 5.0M shares repurchased for $74.9M
  • PRESERVE Phase 4 study targets approximately 150 patients, expanding LUPKYNIS combination-treatment evidence in lupus nephritis

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Aurinia Pharmaceuticals Inc. 8-K filings

Get the next AUPH 8-K as it lands

Follow AUPH for push alerts, or ask the research agent what this filing means.